Administering Bifidobacterium orally can increase dendritic cell (DC) activation, thereby enhancing CD8+ T-cell activation in the tumor microenvironment (TME) and facilitating anti-programmed death-ligand 1 (PD-L1) efficacy [22]. Here, CD274 is linked to neoplasm.